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Increased expression of ARF GTPases 
in prostate cancer tissue
Claire Morgan1*, Paul D Lewis2, Lynda Hopkins3, Stephanie Burnell1, Howard Kynaston4 and Shareen H Doak1
Abstract 
Purpose: ARFs are a family of Ras-related GTP binding proteins, ARF6, in particular, is implicated in cancer invasion 
and metastasis. However, the role of ARF proteins in prostate cancer have yet to be investigated.
Methods: Immunohistochemical staining for ARF6 was performed on a prostate cancer tissue microarray with 
patient matched normal specimens.
Results: Antibody staining was significantly over-expressed in prostate cancer patient samples compared to normal 
patient tissue and a trend towards increased staining intensity in cancer samples with Gleason scores of 8 and above 
(metastatic disease).
Conclusion: Due to high homology between members of the ARF family we could not determine if ARF 6 was the 
only ARF over-expressed in the prostate cancer samples. However, we are the first to show that ARF-GTPases are over 
expressed in prostate cancer which provides further insight into the molecular biology of prostate cancer.
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Background
Prostate cancer (PCa) is the most common cancer in 
men (excluding non melanoma skin cancer) in the UK 
with over 40,000 cases diagnosed each year (Cancer-
ResearchUK 2015). However, for some men with early 
stage PCa that is confined to the prostate the disease 
may never be life threatening and can follow and indo-
lent course which does not require urgent or invasive 
treatment. Unfortunately prostate specific antigen lev-
els (PSA), Gleason score and clinical and pathological 
grading used to diagnose and grade PCa lack the speci-
ficity or sensitivity to distinguish between patients with 
indolent PCa and those requiring radical treatment. 
Changes in PSA can precede clinical disease progres-
sion by months or years. Thus the question of when to 
start therapy in PCa patients can be problematic. This 
poses a significant problem for clinicians when decid-
ing the best treatment for their patients. There is, there-
fore, the clear need for a better understanding of the 
mechanisms involved in the development, progression 
and metastasis of prostate cancer. Key molecular tar-
gets need to be identified that discriminate normal 
tissue from benign tumours and benign tumours from 
aggressive disease and which could also function as tar-
gets of inhibition for future cancer therapeutics.
Adenosine diphosphate-ribosylation factors (ARFs) are 
a family of Ras-related GTP binding proteins. (Li et  al. 
2009). Out of the ARF GTPases, ARF 6 in particular, has 
received much attention; ARF6 functions are concerned 
with actin cytoskeletal remodelling, cell polarity and cell 
migration and thus may have an important role in driving 
carcinogenesis (Donaldson 2003). Indeed, analysis of sev-
eral breast cancer cell lines of differing metastatic capacity 
showed a direct correlation between ARF6 protein expres-
sion and their invasive potential (Hashimoto et al. 2004). 
Elevated levels of activated ARF6 (ARF6-GTP) have been 
found to increase the invasive capacity of melanoma cells 
both in  vitro (Tague et  al. 2004) and in  vivo (Muralid-
haran-Chari et  al. 2009), while silencing ARF6 by small-
interfering RNA inhibits the ability of breast cancer cells to 
invade through an artificial basement membrane, thereby 
providing evidence that ARF6 may be particularly impor-
tant in driving tumour metastasis (Hashimoto et al. 2004). 
Open Access
*Correspondence:  C.Morgan@swansea.ac.uk 
1 Institute of Life Science, Swansea University, Swansea, UK
Full list of author information is available at the end of the article
Page 2 of 4Morgan et al. SpringerPlus  (2015) 4:342 
ARF6, therefore, may be a potential cancer biomarker, 




To determine whether an increased expression of ARF6 
protein (suggestive of increased activity) maybe be found 
in prostate cancer patients we performed immunohisto-
chemistry (IHC) on a commercially available prostate can-
cer tissue microarray (TMA) (AccuMax array, ISU ABXIS, 
Seoul, Korea). The prostate TMA contained 32 prostate 
cancer specimens provided in duplicate along with cor-
responding normal tissue. Two specimens were found 
to be missing in the cancer samples along with two in the 
normal samples bringing the final sample size to 30 cancer 
samples and 30 normal samples. Patient data provided with 
the TMA showed that the age ranged from 44 to 80 years 
(mean 63 years) and Gleason score ranged from 6 to 9. IHC 
was performed using the Benchmark XT automated stain-
ing system (Ventana, AZ) with iViewTM DAB detection kit 
(Ventana, AZ) according to the manufacturer’s instructions. 
After antigen retrieval, anti-ARF6 antibody [(SC-7971) 
Santa Cruz Biotechnology, Germany] was used at 1:50 dilu-
tion at 36°C for 36 min. Intensity of ARF6 immunostaining 
was scored with a four-tiered system (0–3) with 0 represent-
ing no staining, 1 weak staining, 2 moderate staining and 3 
strong staining. A score for staining distribution was also 
applied with 0 representing no staining, 1 < 10% cellular dis-
tribution, 2 between 10 and 60% cellular involvement and 
3 > 60% cellular involvement. The sum score of intensity and 
distribution was then determined (Jan et al. 2009).
Statistical analysis
As IHC staining scores did not follow a normal distribu-
tion, pair-wise comparison of staining patterns between 
normal and cancer samples was carried out using the 
non-parametric Mann–Whitney U-test to determine 
statistical significance. A one-tailed Fisher’s Exact Test 
was used to determine association between staining cat-
egories in tumour and normal tissue with mid-P variant. 
P-values <0.05 were considered significant.
Results
Immunohistochemical analysis using a commercial 
antibody to ARF6 showed a significant increase in the 
observed sum of staining intensity (protein expres-
sion) and distribution between cancer and matched 
normal samples (P  =  0.047, Figure  1). In normal tis-
sue 73% (N =  22) of the samples showed a higher pro-
portion of weak staining intensity relative to moderate 
staining (27%, N =  8) but there were equal numbers of 
cases showing both weak (N = 15) and moderate stain-
ing intensity (N = 15) in tumour tissue (Figure 2). Thus, 
there was an observed higher level of moderate staining 
intensity in tumours relative to normal tissue. Based on 
the hypothesis of increased staining/protein expression 
in tumour samples, the difference was statistically sig-
nificant (P  =  0.044). However, there was no significant 
difference in staining distribution in tumour (score = 2, 
N  =  7; score  =  3, N  =  23) relative to normal tissue 
(score = 2, N = 8; score = 3, N = 22) (P = 0.360). Thus, 
77 and 73% of tumour and normal samples respectively 
showed ARF6 staining in >60% of the tissue sample.
Although the numbers of tumours are relatively small 
in this study, we made a preliminary assessment of the 
patterns of Gleason scores (7, 8 and 9) relative to ARF6 
intensity. Gleason grade 6 was excluded from analysis due 
to small sample size (N = 5). There were a higher propor-
tion of tumours with weak staining (67%, N = 10) com-
pared to moderate staining (33%, N = 5) when Gleason 
score was 7. For cases with Gleason scores ≥8 the pattern 
Figure 1 Immunohistochemical detection of ARF protein expression in a normal prostate tissue and b prostate cancer tissue scored as Gleason 
grade 9.
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is reversed with a higher proportion of moderate staining 
(70%, N = 7) relative to weak staining (30%, N = 3) sug-
gesting a trend towards increased staining intensity with 
increasing Gleason score.
Discussion
ARF6, a member of the ARF family of RAS related 
GTPases, functions in a range of biological activities 
such as adherens junction disassembly (Palacios et  al. 
2001), cell migration (Kondo et  al. 2000) and cell pro-
liferation (Li et  al. 2009). ARF6 has been shown to be 
over-expressed in cancer cells with higher protein levels 
correlating with a highly invasive nature. ARF6 protein 
over expression was found to be between 10 and 20-fold 
higher in highly invasive breast cancer cell lines when 
compared to non-invasive and normal epithelial cells 
(Hashimoto et  al. 2004). In an in  vivo study investigat-
ing ARF6 expression, melanoma growth and metastasis, 
ARF6 was shown to reduce tumour growth but signifi-
cantly increased the invasive capacity of the tumour cells 
(Muralidharan-Chari et  al. 2009). However no studies 
have been conducted on PCa and yet there is a clear need 
for a better understanding of the mechanisms involved 
in its development, progression and metastasis. Key 
molecular targets need to be identified that aid diagno-
sis, discriminate benign tumours from aggressive disease 
and which could also function as targets of inhibition for 
future cancer therapeutics, which makes AFF6 an ideal 
candidate for investigation.
Our aim was to determine if ARF6 protein is over 
expressed in PCa samples when compared to normal 
prostate tissue and to correlate any over expression with 
Gleason score in the hope of elucidating a new PCa bio-
marker. It should be noted that members of the human 
ARF GTPase family are highly homologous with greater 
than 70% sequence identity between the most divergent 
isoforms (ARF1 and ARF6) (Haynes et al. 2007) thus we 
cannot rule out the possibility that the antibody to ARF6 
used in this study is also detecting expression of other 
ARF proteins. However, our preliminary study showed 
ARF antibody staining to be significantly increased in 
PCa samples compared to normal prostate tissue with a 
significantly higher proportion of tumours showing mod-
erate staining intensity compared to normal prostate tis-
sue. In addition, a higher proportion of tumours showed 
weak staining intensity and thus weak protein expression 
compared to moderate staining when Gleason score was 
7, whereas Gleason scores of 8 and above showed a higher 
proportion of moderate staining/protein expression rela-
tive to weak staining suggesting a trend towards increased 
staining intensity with increasing Gleason score.
Conclusion
This study is the first to report the detection and over-
expression of ARF proteins in prostate tissue with a sig-
nificant increase in protein expression in PCa tissues 
compared to normal prostate tissue. While further work 
needs to be undertaken to determine which of the ARF 
proteins are over expressed, our data provides further 
insight into the molecular biology of prostate cancer.
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